123 results on '"Elkrief A"'
Search Results
2. State of the Science: The Hierarchical Taxonomy of Psychopathology (HiTOP)
3. Impact of Keratins 8 and 18 Genetic Variants on the Severity of Alcoholic Liver Disease
4. Porto-sinusoidal vascular liver disorder with portal hypertension: Natural history and long-term outcome
5. Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%–89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab
6. Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies
7. The role and evolution of partial splenic embolization over three decades: A multicentric retrospective single cohort study of 90 patients from French nationwide experience
8. Expert opinion on bleeding risk from invasive procedures in cirrhosis
9. Legionnaires Disease in Solid Organ Transplant Recipients: A Decade-Long Nationwide Study in France
10. Thromboses veineuses splanchniques
11. Splanchnic vein thrombosis associated with SARS-CoV-2 infection: A VALDIG case–control study
12. Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC
13. Hepatocyte-derived biomarkers predict liver-related events at 2 years in Child-Pugh class A alcohol-related cirrhosis
14. Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysis
15. Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification
16. Differential effect of cannabis use on opioid agonist treatment outcomes: Exploratory analyses from the OPTIMA study
17. Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC
18. Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort
19. Variation of the SOFA score and mortality in patients with severe burns: A cohort study
20. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer
21. Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium
22. Non-invasive diagnosis and follow-up of vascular liver diseases
23. Venous thrombotic events in patients treated with immune checkpoint inhibitors for non-small cell lung cancer: A retrospective multicentric cohort study
24. Evolution and phenotypic characterization of whole HBV genome in compliant patients experiencing unexplained entecavir treatment failure
25. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
26. PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis
27. The role of the gut microbiome on radiation therapy efficacy and gastrointestinal complications: A systematic review
28. Traitement de l’ascite réfractaire par alfapump® avec cure de hernie durant la même intervention : une étude rétrospective, multicentrique, européenne chez des patients cirrhotiques
29. Combined treatment of refractory ascites with an alfapump® plus hernia repair in the same surgical session: A retrospective, multicentre, European pilot study in cirrhotic patients
30. Clinical features and evolution of bacterial infection-related acute-on-chronic liver failure
31. Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre study
32. High mortality among hospital-acquired COVID-19 infection in patients with cancer: A multicentre observational cohort study
33. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology
34. Portal cavernoma or chronic non cirrhotic extrahepatic portal vein obstruction
35. Cannabinoids and psychotic symptoms: A potential role for a genetic variant in the P2X purinoceptor 7 (P2RX7) gene
36. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
37. Efficacy of immune checkpoint inhibitors in older patients with non-small cell lung cancer: Real-world data from multicentric cohorts in Canada and France
38. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?
39. Epidemiology and Effects of Bacterial Infections in Patients With Cirrhosis Worldwide
40. Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis
41. LBP-026 The global prospective observational study to evaluate the role of ‘liver transplantation in patients with cirrhosis and severe acuteon-chronic liver failure (CHANCE)’: study design, demographics and overall outcome
42. Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study
43. OP-4 DEVELOPMENT AND EXTERNAL VALIDATION OF A MODEL TO PREDICT MULTI-DRUG RESISTANT BACTERIAL INFECTIONS IN PATIENTS WITH CIRRHOSIS
44. Intravenous ketamine for treatment-resistant depression patients who have failed to respond to transcranial magnetic stimulation: A case series
45. THU-295 - Recent splanchnic vein thrombosis occurring during Sars-Cov-2 infection-The VALDIG study
46. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure
47. P4.11E.17 Clinical Outcomes and Immunotherapy Retreatment in Patients with Metastatic NSCLC Who Complete at Least Two Years of Immune Checkpoint Blockade
48. P2.11B.02 Genomic Correlates of Response to Chemoimmunotherapy in STK11MUT and KEAP1MUT Metastatic Non-Small Cell Lung Cancer
49. P2.11A.12 Machine Learning-Based Clinicogenomic Prediction of Response to PD-(L)1 Inhibition in KRAS Altered Non-Small Cell Lung Cancer
50. Gene- and exon-expression profiling reveals an extensive LPS-induced response in immune cells in patients with cirrhosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.